The proposed bill seeks to establish a new criminal offense in Arkansas known as "prescription drug harm or homicide." This offense is defined under a new section, 5-63-206, which outlines that an executive officer of a pharmaceutical company can be charged if they knowingly conceal dangerous effects of a prescription drug that they have introduced to the market, leading to the death or serious injury of a person who uses the drug. The bill classifies this offense as an unclassified felony, punishable by imprisonment for a term ranging from one year to life.

Additionally, the bill creates the Prescription Drug Harm or Homicide Offense Fund, which will be used to support the prosecution of this new offense. The fund will consist of federal grants, appropriations from the General Assembly, and other authorized revenues. The Attorney General is tasked with utilizing this fund for prosecution purposes. The act is set to expire on December 31, 2026, at which point the relevant sections may be removed from the Arkansas Code, and any remaining funds in the offense fund will be transferred to the General Revenue Fund Account.